Dexmedetomidine 0.4 added
Preclinical
Dexmedetomidine 0.4 added is one of 9 therapeutic programs targeting Bupivacaine. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
14 competitors in Bupivacaine
#DrugCompanyPhaseTrials
1Marcaine
IInnocoll
Approved
EXPAREL
Pacira Pharmaceuticals, IncPhase 3
Bupivacain
IIstanbul University
Phase 2
Ketalar
AAultman Health Foundation
Phase 1
AMPHADASE
AAntares Pharma Inc.
Phase 1
Bupivacaine Liposomes(bl)
HHuazhong University of Science and Technology
Phase 3
Ophthaine
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Warm Bupivacaine
MMansoura University
Preclinical
Dexmedetomidine 0.4 added
MMenoufia University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Dexmedetomidine 0.4 added. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company
- MMenoufia University